Repatha does not currently have a generic version available. As of late 2023, it remains under patent protection [1].
When does Repatha's patent expire?
The exact patent expiration dates for Repatha (evolucumab) are complex due to multiple patents covering different aspects of the drug. However, key patents protecting the drug are expected to expire in the coming years. Some sources indicate potential generic entry around 2027-2028, while others suggest later dates depending on litigation and specific patent challenges [2]. Information on patent expiries can be found on DrugPatentWatch.com [1, 2].
What is Repatha and what is it used for?
Repatha is a prescription medication used to lower low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [3]. It is an injectable PCSK9 inhibitor [4]. Repatha is prescribed for adults with certain types of high cholesterol, including those with familial hypercholesterolemia (a genetic condition), and those who have not been able to reach their LDL cholesterol goals with other cholesterol-lowering treatments [3].
How does Repatha work?
Repatha works by targeting and reducing the PCSK9 protein in the body. PCSK9 normally attaches to LDL receptors on liver cells, preventing them from removing LDL cholesterol from the blood. By inhibiting PCSK9, Repatha allows more LDL receptors to function, leading to a significant reduction in LDL cholesterol levels [4].
Why are companies interested in developing generic Repatha?
The development of generic versions of successful brand-name drugs like Repatha is driven by the potential for significant market share and revenue once patent exclusivity ends. Generic drugs typically enter the market at a lower price point, making them more accessible to a wider patient population and healthcare systems [2]. Pharmaceutical companies actively monitor patent landscapes for opportunities to develop and launch biosimilar or generic versions.
Can biosimilars be developed before patent expiry?
The development and approval pathways for biosimilars are separate from generics. While biosimilars are highly similar to biologic drugs, they are not identical. Patent litigation can affect the timing of biosimilar market entry, and companies may pursue biosimilar development even before all patents have expired, often in anticipation of or in response to patent challenges [2]. Repatha is a biologic drug, meaning its generic version, if approved, would be considered a biosimilar.
What are the alternatives to Repatha?
For individuals needing to lower their LDL cholesterol, alternatives include statins, ezetimibe, and bile acid sequestrants. For those with specific genetic forms of high cholesterol or very high cardiovascular risk, other PCSK9 inhibitors may also be considered, and in some cases, lifestyle changes and diet modifications are foundational components of cholesterol management [3].